Literature DB >> 6230972

Receptors for human IgG subclasses on human alveolar macrophages.

G P Naegel, K R Young, H Y Reynolds.   

Abstract

The biology of individual heavy chain subclasses of human IgG (IgG1-4) in lung host defenses has become important now that specific deficiencies of certain subclasses (IgG2 and IgG4) can be associated with chronic sinopulmonary infections and that IgG4 can be increased in forms of hypersensitivity lung disease. Because IgG is an important opsonic antibody that promotes attachment of bacteria or particles to phagocytes, the relative binding of IgG subclasses to membrane receptors on human alveolar macrophages might predict the efficacy of specific opsonin-mediated phagocytosis. With in vitro cultured normal alveolar macrophages, various IgG complexes were assessed for receptor binding with a rosetting assay. For respiratory cells in culture for 24 h, about 25% of the macrophages bound IgG3 and about 10% bound IgG1; binding with IgG2 and IgG4 complexes was minimal. In macrophage cultures maintained for as long as 6 days, this pattern of binding persisted. However, in very short-term cultures, 30 min and 105 min after cell adherence had occurred, binding was much greater for IgG3 complexes (about 60%); likewise IgG1 and IgG4 bound to about 20% of the cells. The IgM erythrocyte complexes, usually showing no binding at later time points in culture, bound to 20% of the cells, acutely. Therefore, our studies found that IgG3 consistently bound to more alveolar macrophages than the other subclasses, including IgG1. Also, the duration in culture of adherent cells may significantly affect the pattern of binding.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230972     DOI: 10.1164/arrd.1984.129.3.413

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  15 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Immunoglobulin G-induced single ionic channels in human alveolar macrophage membranes.

Authors:  D J Nelson; E R Jacobs; J M Tang; J M Zeller; R C Bone
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

3.  Detection of antigen-specific antibodies on lung tissue in a patient with hypersensitivity pneumonitis.

Authors:  W Popp; O Braun; H Zwick; H Rauscher; L Ritschka; M Flicker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

4.  Immunoglobulins in the lung.

Authors:  D Burnett
Journal:  Thorax       Date:  1986-05       Impact factor: 9.139

5.  Mechanism of Pneumocystis carinii attachment to cultured rat alveolar macrophages.

Authors:  S T Pottratz; W J Martin
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

Authors:  D B Hornick; R B Fick
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

7.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants.

Authors:  P J Watt; M Zardis; P R Lambden
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

Review 9.  Lung humoral response to Pseudomonas species.

Authors:  R B Fick
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

10.  Expression of Fc receptors is suppressed in alveolar macrophages from patients with sarcoidosis.

Authors:  S Hayashi; K Yagawa; M Nakanishi; K Ogata; M Maruyama; N Shigematsu
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.